TNGX
Tango Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$22.72Close
$3.1BMarket cap
$7.51 – $32.9052-week range
Nov 3, 2026Next report
Highlights
Strengths
- Leading the market RS 94 · stronger than 94% of stocks over 12 months
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Far from its high 31% below its 52-week high
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
31%
1wk
down 2.7%
price change
1mo
down 8.9%
price change
12-month return
up 185%
market up 11% ·
its own up 179%
F-score
—
— Not assessed
Altman Z
33.41
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
8.9×
price / book
Earnings yield
down 3.7%
EBIT / enterprise value
Cheaper than
15%
of the market · expensive
Revenue growth
up 48%
year on year
EPS growth
—
latest quarter
Sales growth
down 100%
latest quarter · +0 pts
ROE
down 37%
return on equity
Free cash margin
down 224%
-$139.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
7.9%
$1.80 a day · 2×ATR $19.13
RS
94 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
1.5×
vs 50-day average
Up/down volume
0.96
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 26.2% over the year, from 108m to 136m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 11, 2026
Last shock
Oct 23, 2026-16% in one session4.7× volumeon an SEC filing-3% since
Financials
- Net -163%
- Free cash -224%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $7.7M | $37.0M | $24.9M | $36.5M | $42.1M | $62.4M |
| Operating income | -$52.2M | -$58.2M | -$111.1M | -$114.2M | -$145.6M | -$111.3M |
| Net income | -$52.0M | -$58.2M | -$108.2M | -$101.7M | -$130.3M | -$101.6M |
| Net margin | -679% | -157% | -435% | -278% | -310% | -163% |
| Earnings per share | — | -$0.94 | -$1.23 | -$1.08 | -$1.19 | -$0.87 |
| Free cash flow | $69.0M | -$61.4M | -$116.8M | -$119.5M | -$132.3M | -$139.9M |
| Free cash margin | 901% | -166% | -470% | -327% | -314% | -224% |
| Cash | $28.4M | $142.7M | $60.0M | $66.4M | $69.5M | $112.3M |
| Shareholders' equity | $38.6M | $344.7M | $249.5M | $253.1M | $199.5M | $346.2M |
| Shares outstanding | 40.37m | 87.60m | 88.18m | 102.20m | 107.73m | 135.94m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 5, 2026 | Annual ↗ | Dec 31, 2025 | 64d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 18, 2024 | Annual ↗ | Dec 31, 2023 | 78d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 23, 2026 | Regulation FD · Other events ↗ |
| Aug 11, 2026 | Other events ↗ |
| Aug 11, 2026 | Results ↗ |
| Aug 6, 2026 | Director or officer change ↗ |
| Jun 23, 2026 | Director or officer change ↗ |
| Jun 10, 2026 | Material agreement ↗ |
| Jun 8, 2026 | Regulation FD · Other events ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| May 13, 2026 | Results · Director or officer change ↗ |
| May 8, 2026 | Director or officer change ↗ |
| Apr 15, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 5, 2026 | Results ↗ |